エノボサーム

化学名:エノボサーム

CAS番号.841205-47-8

英語名:Ostarine

CBNumberCB02514763

MFC19H14F3N3O3

MW389.33

MOL File841205-47-8.mol

别名

エノボサーム

(2S)-N-[4-シアノ-3-(トリフルオロメチル)フェニル]-3-(4-シアノフェノキシ)-2-ヒドロキシ-2-メチルプロパンアミド

(S)-オスタリン

エノボサーム物理性質

沸点	632.3±55.0 °C(Predicted)
比重(密度)	1.41±0.1 g/cm3(Predicted)
貯蔵温度	Store at -20°C
溶解性	DMSO:70.0(Max Conc. mg/mL);179.8(Max Conc. mM)
外見	Solid
酸解離定数(Pka)	12.13±0.29(Predicted)
色	White to off-white
InChI	InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1
InChIKey	JNGVJMBLXIUVRD-SFHVURJKSA-N
SMILES	C(NC1=CC=C(C#N)C(C(F)(F)F)=C1)(=O)[C@](O)(C)COC1=CC=C(C#N)C=C1

エノボサーム化学特性,用途語,生産方法

効能
骨粗鬆症治療薬, アンドロゲン受容体モジュレータ
使用
Ostarine is nonsteroidal selective androgen receptor modulator (SARM) used in the treatment of osteoporosis and muscle wasting in animal models. A potential compound for the treatment of hypoactive sexual desire disorder.
Origin
Ostarine is an orally bioavailable, nonsteroidal SARM that was developed by Gtx, Inc. in the late 1990s primarily for the treatment of muscle wasting and osteoporosis.
参考文献
[1] NATALIA LECIEJEWSKA . Sex-specific cytotoxicity of ostarine in cardiomyocytes[J]. Molecular and Cellular Endocrinology, 2023, 577: Article 112037. DOI:10.1016/j.mce.2023.112037.
[2] HARJOT BEDI. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator.[J]. ACG Case Reports Journal, 2021: e00518. DOI:10.14309/crj.0000000000000518.
[3] PJ R, D H, JC C, et al. Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.[J]. Front Endocrinol (Lausanne), 2020, 11: 556581.
[4] JAMES T. DALTON. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial[J]. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2 3: 153-161. DOI:10.1007/s13539-011-0034-6.
[5] ADRIAN S DOBS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.[J]. Lancet Oncology, 2013, 14 4: 335-345. DOI:10.1016/S1470-2045(13)70055-X.
[6] JEFFREY CRAWFORD. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).[J]. Current Oncology Reports, 2016, 18 6: 37. DOI:10.1007/s11912-016-0522-0.
[7] ALVARO MORALES. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.[J]. Canadian Medical Association journal, 2015, 187 18: 1369-1377. DOI:10.1503/cmaj.150033.
[8] Watts D. Ostarine Reviews: shocking results & information about MK2866. SECEC. https://secec.org/ostarine-mk2866/. Accessed May 18, 2020.

エノボサーム生産企業

エノボサームスペクトルデータ(¹HNMR)

841205-47-8, エノボサームキーワード

Send Inquriy

エノボサーム

エノボサーム 化学特性,用途語,生産方法

エノボサーム 生産企業

エノボサーム スペクトルデータ(1HNMR)

841205-47-8, エノボサーム キーワード

エノボサーム化学特性,用途語,生産方法

エノボサーム生産企業

エノボサームスペクトルデータ(¹HNMR)

841205-47-8, エノボサームキーワード